Based on the Supernus Pharmaceuticals Inc stock forecast from 5 analysts, the average analyst target price for Supernus Pharmaceuticals Inc is USD 40.44 over the next 12 months. Supernus Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Supernus Pharmaceuticals Inc is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Supernus Pharmaceuticals Inc’s stock price was USD 31.46. Supernus Pharmaceuticals Inc’s stock price has changed by +2.68% over the past week, +0.64% over the past month and +4.90% over the last year.
No recent analyst target price found for Supernus Pharmaceuticals Inc
No recent average analyst rating found for Supernus Pharmaceuticals Inc
Company Overview Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland. Read Less
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperact...Read More
Frequently Asked Questions About Supernus Pharmaceuticals Inc (SUPN) Stock
Based on ratings from 5 analysts Supernus Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 3 buy, sell and 6 hold ratings.
Unfortunately we do not have enough data on SUPN's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for SUPN is USD 40.44 over the next 12 months. The maximum analyst target price is USD 57 while the minimum anlayst target price is USD 36.
SUPN stock's Price/Earning ratio is 24.36.
Our analysis grades SUPN stock's Price / Earning ratio at F. This means that SUPN stock's Price/Earning ratio is above 51% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this SUPN may be a overvalued for its sector.
The last closing price of SUPN's stock was USD 31.46.
The most recent market capitalization for SUPN is USD 1.79B.
Based on targets from 5 analysts, the average taret price for SUPN is projected at USD 40.44 over the next 12 months.
This means that SUPN's stock price may go up by +28.56% over the next 12 months.
We can't find any ETFs which contains Supernus Pharmaceuticals Inc's stock.
As per our most recent records Supernus Pharmaceuticals Inc has 674 Employees.
Supernus Pharmaceuticals Inc's registered address is 9715 Key West Avenue, Rockville, MD, United States, 20850.
You can get more information about it from Supernus Pharmaceuticals Inc's website at https://www.supernus.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Supernus Pharmaceuticals Inc (SUPN) Stock
Based on ratings from 5 analysts Supernus Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 3 buy, sell and 6 hold ratings.
Unfortunately we do not have enough data on SUPN's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for SUPN is USD 40.44 over the next 12 months. The maximum analyst target price is USD 57 while the minimum anlayst target price is USD 36.
SUPN stock's Price/Earning ratio is 24.36.
Our analysis grades SUPN stock's Price / Earning ratio at F. This means that SUPN stock's Price/Earning ratio is above 51% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this SUPN may be a overvalued for its sector.
The last closing price of SUPN's stock was USD 31.46.
The most recent market capitalization for SUPN is USD 1.79B.
Based on targets from 5 analysts, the average taret price for SUPN is projected at USD 40.44 over the next 12 months.
This means that SUPN's stock price may go up by +28.56% over the next 12 months.
We can't find any ETFs which contains Supernus Pharmaceuticals Inc's stock.
As per our most recent records Supernus Pharmaceuticals Inc has 674 Employees.
Supernus Pharmaceuticals Inc's registered address is 9715 Key West Avenue, Rockville, MD, United States, 20850.
You can get more information about it from Supernus Pharmaceuticals Inc's website at https://www.supernus.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SUPN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
